Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

• DOI: 10.1007/s13277-015-4776-1
• Publication Date: 2016-01-11T06:15:18Z
• Authors: Melike Ozcelik; Taner Korkmaz; Hatice Odabas; Cengiz Gemici; Ozlem Ercelep; Sinemis Yuksel; Aslihan Guven Mert; Heves Surmeli; Deniz Isik; Dincer Aydin; Mesut Seker; Alparslan Mayadagli; Pınar Ozdemir; Mehmet Aliustaoglu; Mahmut Gumus
• Keywords: Concomitant; Carboplatin; Mucositis; Esophagitis

Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard treatment in locally advanced inoperable non-small cell lung cancer (NSCLC). Our study aimed to compare efficacy toxicities three different regimens delivered concurrently with radiotherapy. We retrospectively reviewed clinical records patients who received PE (cisplatin, 50 mg/m2, on days 1, 8, 29, 36 plus etoposide, 1 5 29 33), PD (docetaxel, 20 day cisplatin, every week), PC (carboplatin, AUC 2 paclitaxel, 45 week) A total 227 were evaluated study. Median follow-up time was 13 months (2–101). There 27 females (11.9 %) 200 males (88.1 a median age 61 (38–82) years. The group had higher rates esophagitis, mucositis, anemia (p < 0.05). neuropathy = 0.000). progression-free survival (PFS) 10 for group, 15 21 0.010). Patients overall 23 months, those 0.098). Combination cisplatin-etoposide led more favorable outcome compared other two regimens. It shows generally manageable toxicity profile compliance noticeable.